Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Coleman N, Michalarea V, Alken S, Rihawi K, Lopez RP, Tunariu N, Petruckevitch A, Molife LR, Banerji U, De Bono JS, Welsh L, Saran F, Lopez J.

J Neurooncol. 2018 Aug;139(1):107-116. doi: 10.1007/s11060-018-2847-z. Epub 2018 Apr 10.

PMID:
29637509
2.

Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma.

Michalarea V, Smyth EC.

J Thorac Dis. 2017 Sep;9(9):2868-2870. doi: 10.21037/jtd.2017.08.148. No abstract available.

3.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
4.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
5.

The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.

Kumar R, Geuna E, Michalarea V, Guardascione M, Naumann U, Lorente D, Kaye SB, de Bono JS.

Br J Cancer. 2015 Mar 31;112(7):1157-65. doi: 10.1038/bjc.2015.67.

6.

EGFR-mutated lung cancer in Li-Fraumeni syndrome.

Michalarea V, Calcasola M, Cane P, Tobal K, Izatt L, Spicer J.

Lung Cancer. 2014 Sep;85(3):485-7. doi: 10.1016/j.lungcan.2014.06.017. Epub 2014 Jun 30.

PMID:
25047674
7.

Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.

Williams M, Liu ZW, Woolf D, Hargreaves S, Michalarea V, Menashy R, Kooner I, Wilson E.

J Cancer Res Clin Oncol. 2012 Oct;138(10):1683-8. Epub 2012 May 27.

PMID:
22644996

Supplemental Content

Loading ...
Support Center